Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2159 | Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] Wiki | 1.00 |
| drug1563 | Folic Acid Wiki | 1.00 |
| drug354 | Ascorbic Acid Wiki | 0.50 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately severe symptoms
Description: Safety of UCMSCs will be reported as the percentage of participants in each treatment group that experienced a treatment related SAEs.
Measure: Percent of participants with treatment related Serious Adverse Events (SAE) Time: 12 monthsDescription: Change in serum inflammatory marker levels including Interleukin (IL) IL-6, IL-2, Tumor Necrosis Factor Alpha (TNF-a) and procalcitonin will be evaluated in ng/L.
Measure: Change in inflammatory marker levels Time: Baseline, Day 30Description: Change in serum systemic inflammatory marker levels including D-dimer, high sensitivity C-reactive protein (hsCRP) and ferritin will be evaluated in mg/L.
Measure: Change in systemic inflammatory marker levels Time: Baseline, Day 30Description: Assessed using blood samples or nose/throat swabs.
Measure: COVID-19 Viral Load Time: Up to 30 DaysDescription: Sequential Organ Failure Assessment (SOFA) will be used to assess organ failure including the cardiovascular system, coagulation system, liver, kidney and other extra-pulmonary organs. SOFA score ranges from 0-24 with the higher score indicating worse outcomes.
Measure: Change in SOFA score Time: Baseline, Up to 30 DaysDescription: Sodium, Potassium, Chloride and Carbon Dioxide (CO2) will be evaluated in mmol/L. Changes from baseline to Day 30 will be compared between groups.
Measure: Change in electrolytes levels Time: Baseline, Up to 30 DaysDescription: Serum Lactate Dehydrogenase (LDH) levels assessed in U/L. Changes in LDH from baseline to Day 30 will be compared between groups.
Measure: Change in LDH levels Time: Baseline, Up to 30 DaysDescription: ICU monitoring status will be reported as the number of subjects discharged from the ICU within 7 days.
Measure: Number of subjects discharged from the ICU Time: Up to 7 DaysDescription: Percentage of participants requiring less use of vasoactive agents will be reported.
Measure: Percentage of participants with less requirement for vasoactive agents Time: Up to 30 DaysDescription: Percentage of participant deaths throughout the study period.
Measure: Rate of Mortality Time: Up to 30 DaysDescription: The percentage of participants with changes in serum immune marker levels including Cluster of Differentiation (CD) CD 4+ and CD 8+, as evaluated by treating physician will be reported.
Measure: Percentage of participants with changes in immune marker expression Time: Up to 30 DaysDescription: Percentage of participants with changes in their chest imaging such as ground-glass opacity, local patch shadowing, bilateral patch shadowing and interstitial abnormalities will be reported. Imaging will be assessed by treating physician using chest radiography or chest Computed Tomography (CT).
Measure: Percentage of participants with changes in radiologic findings Time: Up to 30 DaysDescription: Percentage of participants showing less pneumonia symptoms will be reported as evaluated by treating physician using chest radiography or chest CT.
Measure: Percentage of participants with less pneumonia symptoms Time: Up to 30 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports